QMENTA’s hybrid cloud imaging approach combines automated cloud processing with on-premise expert editing for higher accuracy, speed, and...
Compare 6 automated white matter lesion segmentation tools for MS available on QMENTA — including LST-LPA, mediaire Lesion Characterization, SAMSEG,...
Boston, MA, March 29, 2023— QMENTA, Inc. announced today that John E. Kelly III, PhD has been appointed to the company's Board of Advisors. Dr. Kelly...
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
Prof. Russ Hornbeck shares insights on Alzheimer's research and imaging technology through his experience in medical imaging, discussing the DIAN...
A history of multiple sclerosis clinical trials and drug development, from Charcot’s 1868 description to modern DMT approvals and MRI biomarkers.
The 7 trends shaping imaging clinical trials in 2024, including digital twins, decentralized trials, wearables, AI, central reading, psychedelics,...
At RSNA 2022, our team discussed the latest advances in imaging trials software, including state-of-the-art digital biomarkers algorithms.
In order to assure that QMENTA is a reliable trusted partner for managing your medical data, we follow the highest security standards.